Katherine Bergamo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katherine Bergamo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Amy Criego
International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA
1 shared publication - Colleen Bauza
Jaeb Center for Health Research, Tampa, FL, USA
1 shared publication - Daniel J. DeSalvo
Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
1 shared publication - Emily Freiner
Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
1 shared publication - Jennifer L. Sherr
Department of Pediatrics, Pediatric Endocrinology, Yale University School of Medicine, New Haven, USA
1 shared publication - Jill H. Simmons
Division of Pediatric Endocrinology, Vanderbilt University Medical Center, Nashville, TN
1 shared publication
Latest Publications
- Open Access
- 26 October 2023
- Published by Wiley in Pediatric Diabetes
- Vol. 2023, 1-12
Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results
Objective. To further evaluate glycemic outcomes during the observational extension phase of the Continuous Glucose Monitoring (CGM) Intervention for Teens and Young Adults randomized clinical trial (RCT). Subjects and Methods. Following a 26-week RCT comparing CGM with blood glucose monitoring (BGM) in 153 adolescents and young adults aged 14 to Results. In the CGM–CGM cohort, mean hemoglobin A1c (HbA1c) decreased from 8.9% ± 0.9% (74 ± 9.8 mmol/mol) at randomization to 8.3% ± 1.3% (67 ± 14.2 mmol/mol) at 52 weeks ( ); however, significant improvement in time in target range (TIR) 70–180 mg/dL was not observed from prerandomization (38% ± 13%) to 52 weeks (41% ± 18%). Median percent time ). In the BGM–CGM cohort, mean HbA1c decreased from 8.9% ± 1.2% (74 ± 13.1 mmol/mol) before CGM initiation to 8.5% ± 1.3% (69 ± 14.2 mmol/mol) after 26 weeks of CGM use ( ) and mean TIR increased from 34% ± 12% to 38% ± 15% ( ). The median percent time ). No participants discontinued CGM use during the extension phase. Conclusions. This further evaluation of CGM supports the findings of the preceding RCT that use of CGM improves glycemic control and reduces hypoglycemia in adolescents and young adults with type 1 diabetes. This trial is registered with NCT03263494.
- 26 October 2023
- Published by Wiley in Pediatric Diabetes
- Vol. 2023, 1-12
Open AccessContinuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results
Objective. To further evaluate glycemic outcomes during the observational extension phase of the Continuous Glucose Monitoring (CGM) Intervention for Teens and Young Adults randomized clinical trial (RCT). Subjects and Methods. Following a 26-week RCT comparing CGM with blood glucose monitoring (BGM) in 153 adolescents and young adults aged 14 to Results. In the CGM–CGM cohort, mean hemoglobin A1c (HbA1c) decreased from 8.9% ± 0.9% (74 ± 9.8 mmol/mol) at randomization to 8.3% ± 1.3% (67 ± 14.2 mmol/mol) at 52 weeks ( ); however, significant improvement in time in target range (TIR) 70–180 mg/dL was not observed from prerandomization (38% ± 13%) to 52 weeks (41% ± 18%). Median percent time ). In the BGM–CGM cohort, mean HbA1c decreased from 8.9% ± 1.2% (74 ± 13.1 mmol/mol) before CGM initiation to 8.5% ± 1.3% (69 ± 14.2 mmol/mol) after 26 weeks of CGM use ( ) and mean TIR increased from 34% ± 12% to 38% ± 15% ( ). The median percent time ). No participants discontinued CGM use during the extension phase. Conclusions. This further evaluation of CGM supports the findings of the preceding RCT that use of CGM improves glycemic control and reduces hypoglycemia in adolescents and young adults with type 1 diabetes. This trial is registered with NCT03263494.